OncoMatch/Clinical Trials/NCT05536102

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Is NCT05536102 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PLD and Oxaliplatin for gastric cancer.

Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT05536102Data as of May 2026

Treatment: PLD · Oxaliplatin · Capecitabine · Tislelizumab — This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Biomarker criteria

Required: HER2 (ERBB2) negative

HER2-

Required: PD-L1 (CD274) positive

PD-1/L1+

Disease stage

Required: Stage III

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer

Cannot have received: radiation therapy

Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer

Cannot have received: immunotherapy

Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer

Lab requirements

Blood counts

hemoglobin ≥90g/L; ANC ≥1.5×10^9/L; platelets ≥100×10^9/L; serum albumin ≥30g/L

Kidney function

serum creatinine <1 ULN; creatinine clearance >50 ml/min

Liver function

ALT, AST ≤2.5x ULN; serum total bilirubin <1.5 ULN

Cardiac function

LVEF ≥50%; 12-ECG indicates no myocardial ischemia; no history of arrhythmia requiring drug intervention before enrollment

Subject baseline blood routine and biochemical indicators meet the following standards: hemoglobin ≥90g/L; absolute neutrophil count (ANC) ≥1.5×10^9g/L; platelets counts (PLT) ≥100×10^9/L; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal (ULN); serum total bilirubin <1.5 ULN; serum creatinine <1 ULN; serum albumin ≥30g/L. Heart function: Left ventricular ejection fraction (LVEF) ≥50%; 12-ECG indicates no myocardial ischemia; No history of arrhythmia requiring drug intervention before enrollment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify